Impact of blood salvage therapy during oncologic liver surgeries on allogenic transfusion events, survival, and recurrence, an ambidirectional cohort study
CONCLUSION: The use of Cell Saver® should not be avoided in oncologic surgeries of the liver. Use of Cell Saver® for major hepatectomies might be more beneficial as OS was significantly lower for the Cell Saver® group for patients who underwent minor hepactomies. Further research is needed to explain this conflicting result. Nonetheless, the use of Cell Saver® in autologous blood transfusions can reduce the use of valuable resources and the risks associated with allogenic blood transfusions.PMID:38666789 | DOI:10.1097/JS9.0000000000001458
Source: Hand Surgery - Category: Surgery Authors: Liav Lugassy Samuel Marion Fr édéric Balthazar Sonia Gabriela Cheng Oviedo Yves Collin Source Type: research
More News: Blood Transusion | Cancer & Oncology | Liver | Pathology | Study | Surgery | Urology & Nephrology